US10806X1028

Attruby (acoramidis), a Near Complete TTR Stabilizer (90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

- Attruby is the first and only approved product with aspecifying near-complete stabilization of TTR. Attruby has been…

4 weeks ago

Attruby (acoramidis), a Near Complete TTR Stabilizer (90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

- Attruby is the first and only approved product with aspecifying near-complete stabilization of TTR. Attruby has been…

4 weeks ago

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

November 18, 2024 11:15 ET | Source: BridgeBio Pharma, Inc. - Acoramidis demonstrated the earliest known time to separation in…

1 month ago